A new study published in Circulation Research provides novel insights into how mutations in the NOTCH1 gene may lead to abnormal differentiation and proliferation of cardiomyocytes and contribute to ventricular hypoplasia and other structural anomalies found in congenital heart defects in humans.
In 2005, Vidu Garg, MD, a pediatric cardiologist and director of the Center for Cardiovascular Research at Nationwide Children’s Hospital was the lead author of a publication in Nature that first described the link between NOTCH1 mutations and congenital heart disease. Since that publication, mutations in NOTCH1 have been implicated in multiple types of congenital heart defects, including hypoplastic left heart syndrome, in which the left ventricle is underdeveloped.
Though NOTCH signaling is essential for heart development in mammals, it is unknown how the NOTCH1 gene regulates the differentiation and proliferation of human cardiac cells during development. Additionally, the molecular mechanisms leading to ventricular hypoplasia were not understood, says Dr. Garg.
“In this recent study, we investigated how loss of NOTCH1 may actually cause the heart to develop abnormally using human cells,” says Mingtao Zhao, DVM, PhD, a principal investigator in the Center for Cardiovascular Research at Nationwide Children’s.
Dr. Zhao and colleagues used CRISPR/Cas9 gene editing to delete NOTCH1 in human induced pluripotent stem cells (iPSCs) and then differentiate the cells into cardiomyocytes. The research team profiled the transcriptional dynamics of differentiating cells at key developmental stages by single-cell RNA sequencing.
They found that NOTCH1 disruption blocks human ventricular-like cardiomyocyte differentiation but promotes the generation of atrial-like cardiomyocytes. In addition, NOTCH1 deficiency results in defective early cardiomyocyte proliferation, possibly through downregulation of pathways that are involved in cell cycle progression and mitosis.
Single-cell transcriptomic analysis revealed that NOTCH1 disruption promotes the differentiation of some cardiac progenitor cell types from cardiac mesoderm (i.e., epicardial and second heart field progenitors) but inhibits the differentiation of another cell type (i.e., first heart field progenitors).
“These findings provide some insight on the disease mechanisms underlying severe types of congenital heart defects where the left side of the heart is not well formed, such as hypoplastic left heart syndrome,” says study senior author Dr. Zhao, who is also an assistant professor of pediatrics at The Ohio State University College of Medicine.
Since first heart field progenitors primarily contribute to the left ventricle, Dr. Zhao and colleagues suggest that NOTCH1 mutations leading to biased differentiation of these cells, as well as blocking ventricular-like cardiomyocyte differentiation and leading to defective cardiomyocyte proliferation. These collectively may contribute to left ventricular hypoplasia in congenital heart disease.
To further elucidate these mechanisms, the researchers say future studies using iPSCs from hypoplastic left heart syndrome patients with known pathogenic variants in NOTCH1 are needed, as well as experiments in iPSC-derived three-dimensional cardiac organoids.
“If we could better understand why the ventricle is not growing and why the cardiomyocytes are not proliferating, it would open opportunities for therapeutic strategies,” says Dr. Garg, who is also a professor of pediatrics at The Ohio State University College of Medicine and holds the Nationwide Foundation Endowed Chair in Cardiovascular Research.
In 2019, Dr. Zhao established the first human iPSC Genomics Laboratory in the Center for Cardiovascular Research at Nationwide Children’s. Since then, Dr. Zhao, Dr. Garg and their team have created a large iPSC repository using blood samples from more than 100 patients with congenital heart disease.
“With a patient-derived iPSC-based platform, we may find pathways or genes with therapeutic potential” he says. “In the future, we may be able to use a gene therapy or small molecule approach to stimulate cardiomyocyte proliferation during early development."
Ye S, Wang C, Xu Z, Lin H, Wan X, Yu Y, Adhicary S, Zhang JZ, Zhou Y, Liu C, Alonzo M, Bi J, Ramirez-Navarro A, Deschenes I, Ma Q, Garg V, Wu JC, and Zhao MT. 2023. Impaired human cardiac cell development due to NOTCH1 deficiency. Circulation Research. 2022 Dec 30. Doi: 10.1161/CIRCRESAHA.122.321398. Online ahead of print.
About The Abigail Wexner Research Institute at Nationwide Children's Hospital
Named to the Top 10 Honor Roll on U.S. News & World Report’s 2022-23 list of “Best Children’s Hospitals,” Nationwide Children’s Hospital is one of America’s largest not-for-profit free-standing pediatric health care systems providing unique expertise in pediatric population health, behavioral health, genomics and health equity as the next frontiers in pediatric medicine, leading to best outcomes for the health of the whole child. Integrated clinical and research programs are part of what allows Nationwide Children’s to advance its unique model of care. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children’s faculty train the next generation of pediatricians, scientists and pediatric specialists. The Abigail Wexner Research Institute at Nationwide Children’s Hospital is one of the Top 10 National Institutes of Health-funded free-standing pediatric research facilities in the U.S., supporting basic, clinical, translational, behavioral and population health research. The AWRI is comprised of multidisciplinary Centers of Emphasis paired with advanced infrastructure supporting capabilities such as technology commercialization for discoveries; gene- and cell-based therapies; and genome sequencing and analysis. More information is available at NationwideChildrens.org/Research.